FY2025 EPS Estimates for CorMedix Boosted by HC Wainwright

Key Points

• HC Wainwright has raised its FY2025 EPS estimate for CorMedix from $1.41 to $1.96, maintaining a "Buy" rating and a target price of $17.00.
• CorMedix reported Q2 earnings of $0.28 EPS, surpassing consensus estimates and showing significant revenue growth of 4830.1% year-over-year.
• Insiders have sold a total of 163,997 shares over the last ninety days, representing a notable decrease in their ownership stake in the company.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of CorMedix in a report released on Thursday, September 25th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $1.96 for the year, up from their prior estimate of $1.41. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix's Q4 2025 earnings at $0.90 EPS, FY2026 earnings at $2.36 EPS and FY2028 earnings at $2.19 EPS.

Several other equities research analysts have also weighed in on the company. JMP Securities reissued a "market outperform" rating and set a $22.00 target price on shares of CorMedix in a research report on Tuesday, September 9th. Royal Bank Of Canada upgraded shares of CorMedix from an "outperform" rating to a "moderate buy" rating and increased their price target for the company from $13.00 to $17.00 in a research note on Friday, June 20th. Wall Street Zen upgraded shares of CorMedix from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 13th. D. Boral Capital cut shares of CorMedix from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, Needham & Company LLC increased their target price on shares of CorMedix from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, June 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

CorMedix Price Performance

Shares of NASDAQ CRMD opened at $11.30 on Monday. The business has a 50-day moving average of $12.35 and a two-hundred day moving average of $11.31. The company has a market capitalization of $882.08 million, a price-to-earnings ratio of 15.07 and a beta of 1.76. CorMedix has a 1 year low of $5.60 and a 1 year high of $17.43.

CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.08. CorMedix had a net margin of 42.11% and a return on equity of 42.73%. The firm had revenue of $39.74 million during the quarter, compared to the consensus estimate of $29.88 million. During the same quarter in the previous year, the firm posted ($0.25) earnings per share. The company's revenue was up 4830.1% compared to the same quarter last year.

Insider Transactions at CorMedix

In other news, insider Kaufman Beth Zelnick sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $13.41, for a total transaction of $670,500.00. Following the transaction, the insider directly owned 180,418 shares in the company, valued at approximately $2,419,405.38. This trade represents a 21.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Alan W. Dunton sold 10,000 shares of CorMedix stock in a transaction on Friday, September 12th. The shares were sold at an average price of $13.13, for a total transaction of $131,300.00. Following the completion of the transaction, the director directly owned 40,250 shares in the company, valued at $528,482.50. The trade was a 19.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 163,997 shares of company stock valued at $2,163,617 over the last ninety days. 5.30% of the stock is owned by insiders.

Institutional Investors Weigh In On CorMedix

Several hedge funds have recently made changes to their positions in CRMD. Canada Pension Plan Investment Board purchased a new position in shares of CorMedix during the second quarter worth about $42,000. SBI Securities Co. Ltd. lifted its position in CorMedix by 699.7% during the 1st quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company's stock worth $54,000 after acquiring an additional 7,599 shares during the period. USA Financial Formulas purchased a new position in shares of CorMedix in the 2nd quarter valued at approximately $55,000. Essex Financial Services Inc. acquired a new position in shares of CorMedix in the first quarter valued at approximately $63,000. Finally, EntryPoint Capital LLC acquired a new position in shares of CorMedix in the first quarter valued at approximately $66,000. Institutional investors and hedge funds own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.